US 11,857,669 B2
Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
Mitchell Lawrence Jones, La Jolla, CA (US); Sharat Singh, Rancho Santa Fe, CA (US); Christopher Loren Wahl, San Diego, CA (US); and Harry Stylli, La Jolla, CA (US)
Assigned to BIORA THERAPEUTICS, INC., San Diego, CA (US)
Filed by BIORA THERAPEUTICS, INC., San Diego, CA (US)
Filed on May 6, 2021, as Appl. No. 17/313,339.
Application 17/313,339 is a continuation of application No. 16/468,158, granted, now 11,033,490, previously published as PCT/US2017/066492, filed on Dec. 14, 2017.
Claims priority of provisional application 62/583,832, filed on Nov. 9, 2017.
Claims priority of provisional application 62/545,380, filed on Aug. 14, 2017.
Claims priority of provisional application 62/478,919, filed on Mar. 30, 2017.
Claims priority of provisional application 62/434,374, filed on Dec. 14, 2016.
Prior Publication US 2022/0105026 A1, Apr. 7, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 31/519 (2006.01)
CPC A61K 9/0009 (2013.01) [A61K 9/0004 (2013.01); A61K 9/0053 (2013.01); A61K 31/519 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A method of treating a disease of the gastrointestinal (GI) tract in a subject, the method comprising orally administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a Janus Kinase (JAK) inhibitor and not comprising any additional therapeutic agent, and delivering the therapeutically effective amount of the JAK inhibitor at a desired location in the GI tract of the subject, wherein the therapeutically effective amount of the JAK inhibitor is less than an amount that is effective when the JAK inhibitor is administered systemically, wherein the JAK inhibitor is selected from the group consisting of tofacitinib, filgotinib, TD-1473, ruxolitinib, cerdulatinib, momelotinib, oclacitinib, upadacitinib, lestaurtinib, decernotinib, pacritinib, cucurbitacin I, PF-06700841, PF-06651600, PF-04965842, and generic equivalents thereof, and wherein the desired location is proximate to one or more sites of disease.